Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

Review: Imaging of prostate cancer.

18 Jan, 2022 | 09:20h | UTC

Imaging of Prostate Cancer – Deutsches Ärzteblatt International

Related:

ASCO Guideline: Optimum Imaging Strategies for Advanced Prostate Cancer

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer

Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer

Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis

Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management

Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer

Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer

RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy

Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer

Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

 

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.

16 Jan, 2022 | 22:41h | UTC

Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge – Nature Medicine

Commentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet

 

Commentary from one of the authors on Twitter (thread – click for more)

 

European Guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ).

12 Jan, 2022 | 08:32h | UTC

European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) – European Urology

 

M-A of two randomized trials: Among men with high-risk non-metastatic prostate cancer, adding abiraterone and prednisolone to standard androgen-deprivation therapy was associated with improved 6-year metastasis-free survival (82% vs. 69% in the control group).

8 Jan, 2022 | 22:42h | UTC

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol – The Lancet (link to abstract – $ for full-text)

Related Audio: Key messages of the recent report from the STAMPEDE trial platform

 

Systematic Review: Active surveillance for clinically localized prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy.

8 Jan, 2022 | 22:41h | UTC

Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy – European Urology

 

Commentary on Twitter

 

M-A: Adjuvant chemotherapy for muscle-invasive bladder cancer.

17 Dec, 2021 | 08:28h | UTC

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials – European Urology

 

Commentary on Twitter

 

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.

8 Dec, 2021 | 09:45h | UTC

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma – Annals of Oncology

 

Review: Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy.

19 Nov, 2021 | 10:14h | UTC

Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review – JAMA Oncology (free for a limited period)

 

Review: Wilms Tumor.

19 Oct, 2021 | 08:44h | UTC

Wilms tumour – Nature Reviews Disease Primers (free for a limited period)

Infographic: Wilms tumour

 

Commentary on Twitter

 

Review: Recent Advances in the Management of Metastatic Prostate Cancer

1 Oct, 2021 | 09:55h | UTC

Recent Advances in the Management of Metastatic Prostate Cancer – JCO Oncology Practice

 

Clinical Review on the Management of Metastatic Renal Cell Carcinoma.

26 Sep, 2021 | 21:41h | UTC

Clinical Review on the Management of Metastatic Renal Cell Carcinoma – JCO Oncology Practice

 

Cohort study: Half of men with low-risk prostate cancer move from surveillance to treatment within a few years.

27 Aug, 2021 | 08:26h | UTC

Half of men with low-risk prostate cancer move from surveillance to treatment within a few years – Health Imaging

Original study: Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study – Journal of Urology

 

RCT: New blood test could improve prostate cancer screening.

17 Aug, 2021 | 08:48h | UTC

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

News release: New blood test improves prostate cancer screening – Karolinska Institutet

Related:

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

 

Commentary on Twitter

 

Study: many patients with small renal masses can be safely managed with active surveillance.

2 Aug, 2021 | 00:07h | UTC

Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention – The Journal of Urology

Commentary: More Data Support Active Surveillance for Small Renal Masses — Most patients avoided surgery with no metastasis, better focus on aggressive disease – MedPage Today (free registration required)

 

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

9 Jul, 2021 | 10:03h | UTC

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link to abstract – $ for full-text)

News release: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet

Related articles: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer AND Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer AND Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis AND Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer AND Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer AND Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy AND Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer AND Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis AND Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

 

RCT: Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.

24 Jun, 2021 | 09:41h | UTC

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

RCT: Adjuvant Nivolumab vs. Placebo in Muscle-Invasive Urothelial Carcinoma.

3 Jun, 2021 | 10:36h | UTC

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma – New England Journal of Medicine

 

AUA Guideline | Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up.

2 Jun, 2021 | 08:27h | UTC

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up – American Urological Association

Commentary: AUA updates guideline on renal masses and localized renal cancer – Urology Times

 

M-A: A biofeedback‐guided program or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy.

26 May, 2021 | 08:13h | UTC

A biofeedback‐guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta‐analysis and systematic review – The International Journal of Clinical Practice

 

RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.

10 May, 2021 | 00:46h | UTC

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)

 

Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer

4 May, 2021 | 08:26h | UTC

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

 

Commentary on Twitter

 

AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies

29 Apr, 2021 | 08:33h | UTC

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association – Circulation: Genomic and Precision Medicine

News release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association

Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association

Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay

 

Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review

18 Apr, 2021 | 21:16h | UTC

Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review – The Journal of Urology

Commentary: Review: For many men with prostate cancer, surgery risks outweigh potential benefits – U.S. Department of Veteran Affairs

 

M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy

18 Apr, 2021 | 21:14h | UTC

Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis – The Journal of Urology

 

RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy

18 Apr, 2021 | 21:11h | UTC

Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.